Current and historical daily PE Ratio for Nabriva Therapeutics PLC (
) from 2019 to Sep 21 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Nabriva Therapeutics PLC stock (FRA:NTY) PE ratio as of Sep 21 2024 is 0.
More Details
Nabriva Therapeutics PLC (FRA:NTY) PE Ratio (TTM) Chart
Nabriva Therapeutics PLC (FRA:NTY) PE Ratio (TTM) Historical Data
View and export this data going back to 2019. Start your Free Trial
Total 992
- 1
- 2
- 3
- 4
- 5
- 6
- 12
| Nabriva Therapeutics PLC PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-09-21 | At Loss | 2023-06-08 | At Loss |
| 2023-08-09 | At Loss | 2023-06-07 | At Loss |
| 2023-08-08 | At Loss | 2023-06-06 | At Loss |
| 2023-08-07 | At Loss | 2023-06-05 | At Loss |
| 2023-08-04 | At Loss | 2023-06-02 | At Loss |
| 2023-08-03 | At Loss | 2023-06-01 | At Loss |
| 2023-08-02 | At Loss | 2023-05-30 | At Loss |
| 2023-08-01 | At Loss | 2023-05-29 | At Loss |
| 2023-07-31 | At Loss | 2023-05-26 | At Loss |
| 2023-07-28 | At Loss | 2023-05-25 | At Loss |
| 2023-07-27 | At Loss | 2023-05-24 | At Loss |
| 2023-07-26 | At Loss | 2023-05-22 | At Loss |
| 2023-07-25 | At Loss | 2023-05-19 | At Loss |
| 2023-07-24 | At Loss | 2023-05-18 | At Loss |
| 2023-07-21 | At Loss | 2023-05-17 | At Loss |
| 2023-07-20 | At Loss | 2023-05-16 | At Loss |
| 2023-07-19 | At Loss | 2023-05-15 | At Loss |
| 2023-07-18 | At Loss | 2023-05-12 | At Loss |
| 2023-07-17 | At Loss | 2023-05-11 | At Loss |
| 2023-07-14 | At Loss | 2023-05-10 | At Loss |
| 2023-07-13 | At Loss | 2023-05-09 | At Loss |
| 2023-07-12 | At Loss | 2023-05-08 | At Loss |
| 2023-07-11 | At Loss | 2023-05-05 | At Loss |
| 2023-07-10 | At Loss | 2023-05-04 | At Loss |
| 2023-07-07 | At Loss | 2023-05-03 | At Loss |
| 2023-07-06 | At Loss | 2023-05-02 | At Loss |
| 2023-07-05 | At Loss | 2023-04-28 | At Loss |
| 2023-07-04 | At Loss | 2023-04-27 | At Loss |
| 2023-07-03 | At Loss | 2023-04-26 | At Loss |
| 2023-06-30 | At Loss | 2023-04-25 | At Loss |
| 2023-06-29 | At Loss | 2023-04-21 | At Loss |
| 2023-06-28 | At Loss | 2023-04-20 | At Loss |
| 2023-06-27 | At Loss | 2023-04-19 | At Loss |
| 2023-06-26 | At Loss | 2023-04-18 | At Loss |
| 2023-06-23 | At Loss | 2023-04-17 | At Loss |
| 2023-06-22 | At Loss | 2023-04-14 | At Loss |
| 2023-06-21 | At Loss | 2023-04-13 | At Loss |
| 2023-06-20 | At Loss | 2023-04-12 | At Loss |
| 2023-06-19 | At Loss | 2023-04-11 | At Loss |
| 2023-06-16 | At Loss | 2023-04-06 | At Loss |
| 2023-06-15 | At Loss | 2023-04-05 | At Loss |
| 2023-06-14 | At Loss | 2023-04-04 | At Loss |
| 2023-06-13 | At Loss | 2023-04-03 | At Loss |
| 2023-06-12 | At Loss | 2023-03-31 | At Loss |
| 2023-06-09 | At Loss | 2023-03-30 | At Loss |
Nabriva Therapeutics PLC (FRA:NTY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Nabriva Therapeutics PLC
NAICS : 325414
SIC : 2836
ISIN : IE000OZRGNV6
Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers